Disc Medicine, Inc.

Disc Medicine, Inc. (Nasdaq: GMTX) is a clinical-stage biopharmaceutical company focused on developing therapies for serious hematologic diseases, including conditions that impair red blood cell production and bone marrow function. The company was formed through a business combination between legacy Nasdaq-listed Gemphire Therapeutics and private-company Disc Medicine, with the merged entity adopting the Disc Medicine name while retaining the GMTX ticker. Operating in the rare blood disease and hematology sector, the company filed an 8-K current report with the Securities and Exchange Commission on June 14, 2024, under accession number 0001193125-24-161603, disclosing material corporate developments to investors. For complete filing details and comprehensive GMTX coverage, sign up for full access on SpacDesk.